Author

E. Griessinger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:metabolomics· 1

Frequent Co-Authors

G. Huls· 2 shared J. J. Schuringa· 2 shared A. M. de Leal· 1 shared A. P. A. d. L. Lange· 1 shared A. Sahal· 1 shared C. Bosc· 1 shared C. Recher· 1 shared D. A. Pereira-Martins· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Huls

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

FAO-supported OxPhos leukemic stem cells are sensitive to cold.

E. Griessinger, D. Pereira-Martins, M. Nebout, C. Bosc, E. Saland, E. Boet, A. Sahal, J. Chiche, D. Debayle, L. Fleuriot, M. Pruis, V. De Mas, F. Vergez, C. Recher, G. Huls, , J.-F. Peyron

The paper identifies cold sensitivity as a vulnerability in FAO-supported OxPhos leukemic stem cells, which can be exploited for therapeutic targeting.

bioRxiv · Apr 17, 2023 · PreprintCancer Biology

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy

K. Lima, D. A. Pereira-Martins, L. B. L. de Miranda, J. L. Coelho-Silva, G. d. S. Leandro, I. Weinhauser, R. d. C. Cavaglieri, A. M. de Leal, W. F. da Silva, A. P. A. d. L. Lange, E. D. R. P. Velloso, E. Griessinger, J. R. Hilberink, G. Huls, J. J. Schuringa, , J. A. Machado-Neto

This study shows that THZ-P1-2, a PIP4K2 inhibitor, kills leukemia cells by disrupting mitochondrial homeostasis and autophagy, with minimal effects on healthy cells.

bioRxiv · Aug 20, 2022Pharmacology & Toxicology